Filtered By:
Drug: Victoza
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 100 results found since Jan 2013.
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Rev Endocr Metab Disord. 2023 May 26. doi: 10.1007/s11154-023-09807-3. Online ahead of print.ABSTRACTEmerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impair...
Source: ENDOCR REV - May 25, 2023 Category: Endocrinology Authors: Natalia Garc ía-Casares Guillermo Gonz ález-González Carlos de la Cruz-Cosme Francisco J Garz ón-Maldonado Carmen de Rojas-Leal Mar ía J Ariza Manuel Narv áez Miguel Ángel Barbancho Juan Antonio Garc ía-Arnés Francisco J Tinahones Source Type: research
Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: A meta-analysis.
CONCLUSION: GLP1RA therapy when compared to placebo reduced all-cause mortality in high cardiovascular risk patients with type 2 diabetes. They did not impact cardiovascular mortality, nonfatal MI, nonfatal stroke, or heart failure hospitalizations.
PMID: 28413990 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - April 14, 2017 Category: Endocrinology Authors: Peterson S, Barry A Tags: Curr Diabetes Rev Source Type: research
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Publication date: Available online 6 December 2017 Source:The Lancet Diabetes & Endocrinology Author(s): M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular...
Source: The Lancet Diabetes and Endocrinology - December 6, 2017 Category: Endocrinology Source Type: research
Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
ConclusionIn patients prolonging treatment with liraglutide for 5 years, the benefits in relation to metabolic control and CV risk factors are maintained. The UKPDS risk scores suggest that liraglutide is associated with a reduced CHD risk, but not with a reduced stroke risk.
Source: Diabetes Therapy - September 20, 2018 Category: Endocrinology Source Type: research
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions: LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 4, 2013 Category: Cardiology Authors: Steven P. Marso, Neil R. Poulter, Steven E. Nissen, Michael A. Nauck, Bernard Zinman, Gilbert H. Daniels, Stuart Pocock, William M. Steinberg, Richard M. Bergenstal, Johannes F.E. Mann, Lasse Steen Ravn, Kirstine Brown Frandsen, Alan C. Moses, John B. Bus Tags: Trial Design Source Type: research
Treatment of Acute and Chronic Neurological Disorders Using GLP-1, Exendin-4 and Analogs
Glucagon-like peptide-1 (GLP-1) and related peptides, including exendin-4 and liraglutide, are incretin mimetics that enhance glucose-dependent insulin secretion following food ingestion as a regulator of glucose homeostasis. Exendin-4 and liraglutide are used clinically in the safe and effective treatment of type 2 diabetes to enhance insulin secretion and maintain a euglycemic state. These actions are primarily mediated at the level of the GLP-1 receptor in the pancreas; however, these compounds are known to enter the brain where the GLP-1 receptor also is expressed.
Researchers at the NIH have discovered the novel use o...
Source: NIH OTT Licensing Opportunities - April 18, 2012 Category: Research Authors: admin Source Type: research
A new era in the management of type 2 diabetes: is cardioprotection at long last a reality!
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. These two medications act through different mechanisms and has consequently shown different patterns of cardiovascular benefit.
Source: International Journal of Cardiology - November 11, 2016 Category: Cardiology Authors: Xavier Rossello, Derek M. Yellon Tags: Editorial Source Type: research
A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. These two medications act through different mechanisms and has consequently shown different patterns of cardiovascular benefit.
Source: International Journal of Cardiology - November 11, 2016 Category: Cardiology Authors: Xavier Rossello, Derek M. Yellon Tags: Editorial Source Type: research
Delayed administration of the GLP-1 receptor agonist liraglutide improves metabolic and functional recovery after cerebral ischemia in rats
Publication date: 22 February 2017 Source:Neuroscience Letters, Volume 641 Author(s): Wenbin Dong, Yunping Miao, Aiying Chen, Min Cheng, Xiaodi Ye, Fahuan Song, Gaoli Zheng Glucagon-like peptide 1 receptor (GLP-1R) agonists administered before or immediately after induction of experimental stroke have been shown to provide acute neuroprotection. Here, we determined whether delayed treatment with a GLP-1R agonist could improve metabolic and functional recovery after stroke. Rats were subjected to middle cerebral artery occlusion (MCAO) and given the well-established GLP-1R agonist liraglutide (50, 100, or 200μg/kg) or nor...
Source: Neuroscience Letters - January 22, 2017 Category: Neuroscience Source Type: research
Cardiovascular safety outcomes of new antidiabetic therapies.
CONCLUSION: A review of cardiovascular safety outcomes for new antidiabetic agents found that saxagliptin and alogliptin were associated with an increase in hospitalization for HF. The data for empagliflozin, liraglutide, and semaglutide showed a reduction in cardiovascular events and death or a neutral effect on cardiovascular endpoints.
PMID: 28483748 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - May 8, 2017 Category: Drugs & Pharmacology Authors: LeBras MH, Barry AR, Koshman SL Tags: Am J Health Syst Pharm Source Type: research
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
CONCLUSIONS: There is no firm evidence that DPP-4 inhibitors or GLP-1 analogues compared mainly with placebo substantially influence the risk of T2DM and especially its associated complications in people at increased risk for the development of T2DM. Most trials did not investigate patient-important outcomes.
PMID: 28489279 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 10, 2017 Category: General Medicine Authors: Hemmingsen B, Sonne DP, Metzendorf MI, Richter B Tags: Cochrane Database Syst Rev Source Type: research
FDA clears Nordisk ’s Victoza as only Type II diabetes drug to cut cardio risks
The FDA approved a new indication for Novo Nordisk‘s (NYSE:NVO) Victoza liraglutide injection, clearing it as the only Type II diabetes medication indicated to reduce the risk of cardiovascular diseases, like heart attack and stroke.
The regulatory watchdog’s decision is based on results from Nordisk’s 9,300-patient Leader trial, which showed that Victoza significantly reduced the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA clears Nordisk’s Victoza as only Type II diabetes drug to cut cardio risks appear...
Source: Mass Device - August 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news
